XRX-008
Renal Disease associated with Type 2 Diabetes
PreclinicalActive - Program in Development
Key Facts
Indication
Renal Disease associated with Type 2 Diabetes
Phase
Preclinical
Status
Active - Program in Development
Company
About XORTX Therapeutics
XORTX Therapeutics is a clinical-stage biotech focused on developing treatments for progressive kidney diseases driven by elevated uric acid. Its core achievement is advancing oxypurinol, a xanthine oxidase inhibitor, into a pivotal Phase 3 trial (XRX-OXY-301) for ADPKD, a condition with no approved disease-modifying therapies. The company's strategy leverages established drug safety to de-risk development while targeting a significant unmet medical need. Success in its Phase 3 trial would validate its scientific hypothesis and create substantial value.
View full company profile